55
Participants
Start Date
March 12, 2019
Primary Completion Date
October 5, 2022
Study Completion Date
October 5, 2022
Rivaroxaban
Rivaroxaban 20 mg daily (15 mg daily in participants with a CrCl 30-49 mL/min as per the Cockroft-Gault equation)
Standard of care
Accepted standard of care as per American Heart Association/American Stroke Association Guidelines (initial use of unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist or continuation with low-molecular weight heparin) with choice of agent at the treating physician's discretion.
Foothills Medical Centre, Calgary
University of Alberta Hospital, Edmonton
Kelowna General Hospital, Kelowna
Vancouver General Hospital, Vancouver
Hamilton Health Sciences Centre, Hamilton
London Health Sciences Centre, London
The Ottawa Hospital Research Institute, Ottawa
Sunnybrook Health Sciences Centre, Toronto
Toronto Western Hospital, Toronto
Centre hospitalier de l'Université de Montréal, Montreal
Royal University Hospital, Saskatoon
University of British Columbia
OTHER